RAF MUTATION
Clinical trials for RAF MUTATION explained in plain language.
Never miss a new study
Get alerted when new RAF MUTATION trials appear
Sign up with your email to follow new studies for RAF MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted cancer drug shows promise but study halted early
Disease control TerminatedThis study tested a drug called tovorafenib in people aged 12 and older whose cancers had returned or worsened and had certain gene changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, so results are limited.
Matched conditions: RAF MUTATION
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 01:33 UTC
-
New cancer drug trial halted early: what we know
Disease control TerminatedThis early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see…
Matched conditions: RAF MUTATION
Phase: PHASE1 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 13, 2026 16:04 UTC